C16 Ceramide (d18:1/16:0)
(Synonyms: N-棕榈酰神经鞘氨醇,Palmitoyl Ceramide) 目录号 : GC43028C16 神经酰胺(d18:1/16:0)是一种内源性神经酰胺,由神经酰胺合成酶 6(CerS6)生成,作为脂质第二信使调控细胞凋亡和应激信号。
Cas No.:24696-26-2
Sample solution is provided at 25 µL, 10mM.
C16 ceramide (d18:1/16:0), as an endogenous ceramide, generated by ceramide synthase 6 (CerS6), that acts as a lipid second messenger to regulate apoptosis and stress signaling[1]. C16-ceramide plays a pivotal role in inducing insulin resistance[2].
In vitro, treatment with 100 µM synthetic C16 ceramide (d18:1/16:0), or accumulation of C16 ceramide (d18:1/16:0) through PPMP (30 µM) (namely, a selective inhibitor of glucosylceramide synthase) or MAPP (50 µM) (namely, a specific ceramidase inhibitor) induces apoptosis in neutrophil cultures via caspase-3 activation[3]. In vitro, 12 µM C16-ceramide treatment in HCT116 cells induces EMD (emerin) phosphorylation[4]. In vitro, 1 µM C16 ceramide partially rescued the LASP1-actin (play a role in cell migration) interaction under a CERS6 silencing condition[5]. Exogenous C16-ceramide (20 µM) and acid sphingomyelinase induced trophoblast apoptosis, an effect abrogated completely by cotreatment with 10 ng/ml EGF(epidermal growth factor)[6].
References:
[1]White-Gilbertson S, et al. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene. 2009 Feb 26;28(8):1132-41.
[2]Chathoth S, et al. Insulin resistance induced by de novo pathway-generated C16-ceramide is associated with type 2 diabetes in an obese population. Lipids Health Dis. 2022 Feb 20;21(1):24.
[3]Seumois G, et al. De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis. J Leukoc Biol. 2007 Jun;81(6):1477-86.
[4]Deroyer C, et al. New role for EMD (emerin), a key inner nuclear membrane protein, as an enhancer of autophagosome formation in the C16-ceramide autophagy pathway. Autophagy. 2014 Jul;10(7):1229-40.
[5]Payne SG, et al. Epidermal growth factor inhibits ceramide-induced apoptosis and lowers ceramide levels in primary placental trophoblasts. J Cell Physiol. 1999 Aug;180(2):263-70.
C16 神经酰胺(d18:1/16:0)是一种内源性神经酰胺,由神经酰胺合成酶 6(CerS6)生成,作为脂质第二信使调控细胞凋亡和应激信号[1]。C16 神经酰胺在诱导胰岛素抵抗中起着关键作用[2]。
在体外,用 100 µM 合成 C16 神经酰胺(d18:1/16:0)处理细胞,或通过 PPMP(30 µM)即一种葡萄糖甘油酰胺合成酶选择性抑制剂)或 MAPP(50 µM)(即一种特异性神经酰胺酶抑制剂) 积累的C16 神经酰胺(d18:1/16:0),可通过 caspase-3 激活诱导中性粒细胞凋亡[3]。在体外,用12 µM C16 神经酰胺处理 HCT116 细胞可诱导 EMD(emerin)磷酸化[4]。在体外,1 µM C16 神经酰胺可部分缓解 CERS6 沉默条件下 LASP1 与肌动蛋白(在细胞迁移中发挥作用)之间的相互作用[5]。外源性C16-神经酰胺(20 µM )和酸性鞘磷脂酶可诱导滋养细胞凋亡,与 10 毫微克/毫升 EGF(表皮生长因子)共处理可完全消除这种效应[6]。
| Cell experiment [1]: | |
|
Cell lines |
SW620 cells |
|
Preparation Method |
Exogenous C16 ceramide sensitizes tumor cell to Fas-mediated apoptosis. SW620 cells were treated with C16 ceramide for 1 h at the indicated concentrations (0 - 3 µM ), and then cultured in the absence or presence of FasL for approximately 24 h. |
|
Reaction Conditions |
0 - 3 µM; 24h |
|
Applications |
Exogenous C16 ceramide directly induced apoptosis in a dose-dependent manner, albeit at a low level, exogenous C16 ceramide significantly increased SW620 cell sensitivity to FasL-induced apoptosis。 |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6J mice |
|
Preparation Method |
Mice received repeated DH (the dorsal hippocampus) or BLA (the basolateral amygdala) infusions of vehicle, C8 ceramide ((d18:1/8:0); 2 µM/0.2 µL/side), C16 ceramide ((d18:1/16:0); 2 µM/0.2 µL/side), or C20 ceramide ((d18:1/20:0); 2 µM/0.2 µL/side). |
|
Dosage form |
2 µM/0.2 µL/side; Intracerebral infusions. |
|
Applications |
C16 ceramide induced a depressive-like phenotype when infused into the DH(the dorsal hippocampus), but a predominantly non-social anxiogenic-like phenotype when infused into the BLA(the basolateral amygdala). |
|
References: [1] Paschall AV, et al. Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression. BMC Cancer. 2014 Jan 15;14:24. | |
| Cas No. | 24696-26-2 | SDF | |
| 别名 | N-棕榈酰神经鞘氨醇,Palmitoyl Ceramide | ||
| 化学名 | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-hexadecanamide | ||
| Canonical SMILES | CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](NC(CCCCCCCCCCCCCCC)=O)CO | ||
| 分子式 | C34H67NO3 | 分子量 | 537.9 |
| 溶解度 | DMF : 10 mg/mL (ultrasonic and warming and heat to 55°C) | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8591 mL | 9.2954 mL | 18.5908 mL |
| 5 mM | 0.3718 mL | 1.8591 mL | 3.7182 mL |
| 10 mM | 0.1859 mL | 0.9295 mL | 1.8591 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet